Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $67.70.
JANX has been the topic of several research reports. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Wedbush reissued an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research report on Thursday, August 8th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, November 7th. Finally, UBS Group assumed coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company.
Check Out Our Latest Report on Janux Therapeutics
Insider Buying and Selling at Janux Therapeutics
Hedge Funds Weigh In On Janux Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after buying an additional 7,442 shares in the last quarter. Virtu Financial LLC increased its holdings in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Janux Therapeutics during the 3rd quarter valued at approximately $940,000. Geode Capital Management LLC lifted its stake in Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after purchasing an additional 38,490 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.
Janux Therapeutics Trading Down 2.5 %
Shares of Janux Therapeutics stock opened at $45.21 on Tuesday. The company has a 50-day moving average of $49.81 and a two-hundred day moving average of $45.78. The stock has a market cap of $2.37 billion, a PE ratio of -38.64 and a beta of 3.52. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $65.60.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The firm’s revenue was down 82.6% compared to the same quarter last year. On average, sell-side analysts forecast that Janux Therapeutics will post -1.35 EPS for the current fiscal year.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Featured Articles
- Five stocks we like better than Janux Therapeutics
- 10 Best Airline Stocks to Buy
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 11/25 – 11/29
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.